GSK’s travel plans, or lack thereof
Executive Summary
GlaxoSmithKline responds to an article in 1"The Pink Sheet" (April 3, 2006, p. 8) discussing international mergers. "The article quotes comments made by Clifford Kalb, VP of Life Sciences at Wood Mackenzie, speculating on future mergers expected in the pharmaceutical industry," GSK notes. "Among those comments, the article references Mr. Kalb as saying that GlaxoSmithKline's CEO 'recently visited the offices of New Jersey Governor Jon Corzine seeking a tax break to relocate the firm's headquarters.' Mr. Kalb's speculation is completely wrong. The company's CEO has not met with Governor Corzine, and GlaxoSmithKline has no intention of moving its headquarters from the UK to the U.S.," GSK says...
You may also be interested in...
Sanofi-Aventis May Be First In Wave Of National Pharma; Will Swiss Follow?
Sanofi-Synthelabo's merger with Aventis may be the first in a trend towards the creation of national pharma companies that could include the formation of "Pharma Swiss," according to Wood Mackenzie VP-Life Sciences Clifford Kalb
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.